Table 1.
Demographic and clinical characteristics of the entire cohort at the time of diagnosis.
| sAIE | iAIE | |||
|---|---|---|---|---|
| Age at onset1 | 49.36 | (19.74) | 53.27 | (15.2) |
| Females2 | 10 | (45) | 10 | (90) |
| Time from onset to LP3 | 62.50 | (0-1778) | 379.00 | (15-2284) |
| Antibody2 | ||||
| LGI1 | 8 | (36) | ||
| NMDAR | 7 | (32) | ||
| CASPR2 | 3 | (14) | ||
| IgLON5 | 3 | (14) | ||
| AMPAR | 1 | (4) | ||
| GAD65/67 | 4 | (36) | ||
| Yo (PCA1) | 3 | (27) | ||
| Ma-1/2 | 2 | (18) | ||
| CV2 (CRMP5) | 2 | (18) | ||
| Symptoms at onset2 | ||||
| Psychiatric | 10 | (45) | 2 | (18) |
| Cognitive | 10 | (45) | 1 | (9) |
| Seizure | 8 | (36) | 1 | (9) |
| Movement | 5 | (23) | 9 | (82) |
| MRI abnormalities2 | 17 | (77) | 4 | (37) |
| Tumor2 | 4 | (18) | 7 | (63) |
1mean and standard deviation 2number (percentage) 3median and min-max in days; NMDAR, N-methyl-D-aspartate receptor; LGI1, leucine-rich glioma-inactivated 1; CASPR2, contactin-associated protein-like 2; AMPAR, amino-3-hydroxy-5-hydroxy-5-methyl-4-isoxazolepropionic acid receptor; ANNA, anti-neuronal nuclear antibody; CRMP, collapsin response-mediator protein-5, sAIE cell-surface antibody-associated AIE; iAIE antibodies against intracellular antigen-associated AIE.